Moderna Approves $900 Million+ Golden Parachute for CEO After Company Went From Losing $747 M In 2020 to Making $12.2 B in 2021 With JAB

Two things are certain with pandemics – one, some people are going to die; and two, some people are going to make a lot of cash.

Along with Pfizer-BioNTech, US-based vaccine manufacturer Moderna Inc. has been one of the largest beneficiaries of all following the release of the Fauci-funded Chinavirus from the Wuhan lab in early 2020. Over the past two years, the company has undergone an unthinkable turnaround from where it was before the pandemic hit, posting revenues of over $12,000,000,000 ($12B) in 2021 after losing a whopping $747 million in 2020.

What’s most astonishing about the change in fortune is that the entirety of Moderna’s income is attributable to the only commercially available product it offers: the experimental mRNA Covid-19 vaccine.

We are primarily funded by readers. Please subscribe and donate to support us!

With sales from the vaccine expected to top last year’s numbers, the company has decided to reward its top executive, CEO Stephanie Bancel, with a massive ‘change-in-control’ package that will pay him upwards of $900 million dollars if the company is sold or merged and he loses his job in the process.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.